Browse > Article

MDM2, p53 and pRb Expression Prior to Definitive Chemoradiotherapy in Esophageal Carcinoma  

Yoon, Mee-Sun (Departments of Radiation Oncology, Chonnam National University Medical School)
Lee, Jae-Hyuk (Departments of Pathology, Chonnam National University Medical School)
Cho, Sang-Hee (Departments of Internal Medicine, Chonnam National University Medical School)
Song, Ju-Young (Departments of Radiation Oncology, Chonnam National University Medical School)
Ahn, Sung-Ja (Departments of Radiation Oncology, Chonnam National University Medical School)
Chung, Ik-Joo (Departments of Internal Medicine, Chonnam National University Medical School)
Chung, Woong-Ki (Departments of Radiation Oncology, Chonnam National University Medical School)
Nah, Byung-Sik (Departments of Radiation Oncology, Chonnam National University Medical School)
Nam, Taek-Keun (Departments of Radiation Oncology, Chonnam National University Medical School)
Publication Information
Radiation Oncology Journal / v.25, no.4, 2007 , pp. 193-200 More about this Journal
Abstract
Purpose: This study evaluated the pretreatment expression patterns of MDM2, p53, and pRb proteins to determine if the expression patterns could predict the outcome of concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma and aid in the decisions for the selection of treatment modalities. Materials and Methods: Fifty-one patients that were treated with definitive chemoradiotherapy for stage $I{\sim}IVa$ esophageal squamous cell carcinoma were selected for this study. Radiotherapy was administered with daily $1.8{\sim}2\;Gy$ fractions up to a median dose of 54 Gy for primary tumors, and with four cycles of cisplatin/5-fluorouracil chemotherapy that was administered every 4 weeks, the first two cycles of which were administered concurrently with radiotherapy. Expression of MDM2, p53, and pRb was investigated by immunohistochemical analysis using pretreatment biopsy specimens. Results: MDM2, p53, and pRb were detected with high immunoreactivity in 19.6%, 27.5%, and 66.7% of the patients, respectively. However, there was no significant correlation between expression of these factors and clinical outcome. By the use of multivariate analysis with nine covariates-age, tumor location, tumor length, stage, pathological response, clinical response, MDM2 expression, p53 expression, and pRb expression, only pathological response and stage were significant factors for cause-specific survival. Conclusion: Expression of MDM2, p53, and pRb was not found to be clinically significant for predicting outcomes after CCRT in this study. Further studies with a larger patient population and longer follow-up periods are needed to re-evaluate the expression pattern and to identify new predictors for CCRT response.
Keywords
Esophageal neoplasms; Chemoradiotherapy; MDM2; p53; pRb; Immunohistochemistry;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pearson JG. The present status and future potential of radiotherapy in the management of esophageal cancer. Cancer 1977;39(2 Suppl):882-890   DOI   ScienceOn
2 Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-284   DOI
3 Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245   DOI   ScienceOn
4 Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M, Tominaga T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 1998;89:221- 227   DOI   PUBMED
5 Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993; 53:846-850   PUBMED
6 American Joint Committee on Cancer. Manual for staging of cancer. 6th ed. Philadelphia, PA: Lippincott Co. 2002: 57-61
7 Lim JT, Truong PT, Berthelet E, et al. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003;57:1328-1335   DOI   ScienceOn
8 Soslow RA, Altorki NK, Yang G, Xie D, Yang CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999;12:580-586   PUBMED
9 Ikeguchi M, Ueda T, Fukuda K, Yamaguchi K, Tsujitani S, Kaibara N. Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am J Clin Oncol 2002;25:454-459   DOI   ScienceOn
10 Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958- 9961   DOI
11 Puglisi F, Di Loreto C, Panizzo R, et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 1996;49:456-459   DOI
12 Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330   DOI   ScienceOn
13 Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003;7:77-86 discussion 86-87   DOI   ScienceOn
14 Landers JE, Haines DS, Strauss JF 3rd, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9:2745-2750   PUBMED
15 Hennequin C, Gayet B, Sauvanet A, et al. Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus. Int J Radiat Oncol Biol Phys 2001;49:657-664   DOI   ScienceOn
16 Seitz JF, Perrier H, Monges G, Giovannini M, Gouvernet J. Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53. Gastroenterol Clin Biol 1995;19:465-474
17 Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375:694-698   DOI   ScienceOn
18 Shimada Y, Imamura M, Shibagaki I, et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg 1997;226:162-168   DOI
19 Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003;9:6461-6468   PUBMED
20 Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 1991;51:5766-5769   PUBMED
21 Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53(10 Suppl):2231-2234   PUBMED
22 Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000;2:569-573   DOI   ScienceOn
23 Ito T, Kaneko K, Makino R, et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 2001;36:303-311   DOI
24 Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined- modality approach. Cancer 2004;100:1859-1867   DOI   ScienceOn
25 Araujo CM, Souhami L, Gil RA, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 1991;67:2258-2261   DOI   ScienceOn
26 Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83:7-18   DOI   ScienceOn
27 Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23:2310-2317   DOI   ScienceOn
28 Hur HK, Rha SH, Hong SH. Expression pattern of the Rb protein and its correlation with prognosis in primary lung cancer. Korean J Pathol 1997;31:152-161
29 Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996;14:156-163   DOI   PUBMED
30 Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331   DOI   ScienceOn
31 Shimoji H, Miyazato H, Nakachi A, et al. Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus 2000;13:185-190   DOI   ScienceOn
32 Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357- 365   DOI   ScienceOn
33 Kim JH, Choi EK, Kim SB, et al. Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2001; 50:1-12   DOI   ScienceOn
34 Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-468   PUBMED
35 Meng RD, Shih H, Prabhu NS, George DL, el-Deiry WS. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin Cancer Res 1998;4:251-259   PUBMED